Literature DB >> 3081046

Characterization of a monoclonal antibody that binds equally to all apolipoprotein and lipoprotein forms of human plasma apolipoprotein B. I. Specificity and binding studies.

E Koren, D Solter, D M Lee, Z Reiner, W J McConathy, N Dashti, P Alaupovic.   

Abstract

A stable mouse hybridoma cell line has been developed that produces monoclonal antibody to human plasma apolipoprotein B. This antibody was proven to be specific for apolipoprotein B immunoblotting and an enzyme immunoassay using apolipoprotein B and other apolipoproteins. The antibody bound with comparable affinities to soluble apolipoprotein B, chylomicrons, very-low-density (VLDL) and low-density lipoproteins (LDL). Coupled to agarose, this antibody allowed complete removal of apolipoprotein B-containing lipoproteins from normolipidemic, hypertriglyceridemic and hypercholesterolemic plasma. Desialyzation and deglycosylation had no effect on its binding to LDL. The described antibody had no effect on the receptor-mediated binding of radiolabeled LDL to the human hepatoma cells (HepG2) in culture. Analysis of 25 different samples of human plasma indicated identical expression of the corresponding epitope in these individuals. The described monoclonal antibody, most likely, binds to a rather stable domain of apolipoprotein B that is not altered by the interaction with lipids or polymorphism of the apolipoprotein B. We propose that this antibody be called 'Pan B' antibody.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081046     DOI: 10.1016/0005-2760(86)90321-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Identification of Escherichia coli DNA helicase IV with the use of a DNA helicase activity gel.

Authors:  V N Trieu; D McCarthy
Journal:  J Bacteriol       Date:  1989-04       Impact factor: 3.490

2.  Methylamine-treated low density lipoproteins elicit different responses in HepG2 cells and macrophages.

Authors:  E Koren; N Dashti; P R Wilson; D M Lee
Journal:  Mol Cell Biochem       Date:  1993-07-07       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.